Roche to Present Ophthalmology Data at ARVO 2026
Roche will showcase its ophthalmology portfolio at the ARVO Annual Meeting from May 3-7, 2026, in Denver, Colorado. The presentation will feature new real-world data on Vabysmo and Susvimo, focusing on their effectiveness for various retinal conditions, including diabetic macular edema and age-related macular degeneration. Additionally, promising data on an investigational IL-6 inhibitor, vamikibart, will be presented.
Basel, 30 April 2026 – Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that it will showcase key real-world, product and pipeline data from its ophthalmology portfolio at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, held 3rd to 7th of May in Denver, Colorado, USA. The data being presented emphasise Roche’s focus on preserving vision through innovative therapies, including Vabysmo® (faricimab), Susvimo® (Port Delivery Platform with ranibizumab) and the investigational interleukin-6 (IL-6) inhibitor, vamikibart. The data cover five retinal conditions including geographic atrophy (GA), retinal vein occlusion (RVO) and uveitic macular edema (UME) as well as diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD).